Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT02270359Active, not recruiting
Single-arm trial, sponsored by NYU Langone Health. Primary endpoint: Prevalence of plaque disruption at 1 week. Started Apr 2014; status: active, not recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT02270359.